Physicians

The Kent and Siri Rawson Director, Program for Advanced Coronary Disease Associate Director, Duke Heart Center Senior Investigator, Duke Clinical Research Institute

Department / Division
Medicine / Medicine - Cardiology

Address
DUMC 3126
Durham, NC 27710

Appointment Telephone
919-681-5816

Office Telephone
919-681-2069

Fax Telephone
919-681-0811

Training

• MD, Royal College of Surgeons in Ireland, 1981

Residency

• General Internal Medicine, Saint Laurence's Hospital, Saint Vincent's Hospital (Ireland), 1981-1984

Fellowship

• Cardiology (Research), Saint Laurence's Hospital (Ireland), 1984-1987
• Cardiology, Duke University Medical Center, 1987-1991

Other Training

• Fellow, American College of Cardiology
• Fellow, European Society of Cardiology
• Fellow, Royal College of Physicians (Ireland)
• Fellow, Society for Cardiovascular Angiography and Interventions

Clinical Interests
Interventional cardiology, treatment of advanced/complex coronary disease, primary or secondary prevention

Research Interests
The main focus of my research is in the management of acute myocardial infarction. My focus has revolved around the use of interventional procedures such as balloon angioplasty, intra-aortic balloon pumping and other support devices for the management of patients with acute myocardial infarction. Through participating and designing a number of randomized trials, we have helped crystallize the management to sustain patency of the infarct-related coronary artery in acute myocardial infarction. Furthermore, I have conducted several large multi-center clinical trials on the use of intra-aortic counterpulsation and angioplasty to better understand the pathophysiology of interventional procedures. Another major focus has been in the area of risk stratification in acute myocardial infarction. Early observations done abroad have led me to use new cardiac markers to identify high and low risk patients. Further research in this area will integrate early and rapid triage along with monitoring of the effect of thrombolysis after reperfusion in patients. A patent in the latter category has already been issued. My continued focus in the performance of multi-center international clinical trials has allowed us to explore different treatment strategies for the management of acute myocardial infarction from an international prospective. We have also collected angioplasty data on nearly 6,000 patients from around North America to further explore international differences in the management of patients using percutaneous interventions.

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Abiomed, Inc.
• AstraZeneca
• Biotie
• Bristol-Myers Squibb
• Daiichi Sankyo Co., Ltd
• Eli Lilly & Co.
• Faculty Connection
• Gilead Sciences, Inc.
• GlaxoSmithKline
• Hoffman LaRoche (Roche Holding)
• Ikaria
• Ivivi
• Janssen Pharmaceuticals (Johnson & Johnson)
• LipoScience, Inc.
• Merck
• Pozen
• Sanofi-Aventis
• The Medicines Company
• WebMD

Representative Publications
Chen, EW; Canto, JG; Parsons, LS; Peterson, ED; Littrell, KA; Every, NR; Gibson, CM; Hochman, JS; Ohman, EM; Cheeks, M; Barron, HV; Investigators in the National Registry of Myocardial Infarction 2. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation. 2003;108:951-957. (2003) Abstract

Kaul, P; Newby, LK; Fu, Y; Hasselblad, V; Mahaffey, KW; Christenson, RH; Harrington, RA; Ohman, EM; Topol, EJ; Califf, RM; Van de Werf, F; Armstrong, PW; PARAGON-B Investigators. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. Journal of the American College of Cardiology. 2003;41:371-380. (2003) Abstract

Khot, UN; Khot, MB; Bajzer, CT; Sapp, SK; Ohman, EM; Brener, SJ; Ellis, SG; Lincoff, AM; Topol, EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA: Journal of the American Medical Association. 2003;290:898-904. (2003) Abstract

Ottervanger, JP; Armstrong, P; Barnathan, ES; Boersma, E; Cooper, JS; Ohman, EM; James, S; Topol, E; Wallentin, L; Simoons, ML; GUSTO IV-ACS Investigators. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. Circulation. 2003;107:437-442. (2003) Abstract

Stone, GW; Ohman, EM; Miller, MF; Joseph, DL; Christenson, JT; Cohen, M; Urban, PM; Reddy, RC; Freedman, RJ; Staman, KL; Ferguson, JJ. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. Journal of the American College of Cardiology. 2003;41:1940-1945. (2003) Abstract

Sánchez, CD; Newby, LK; Hasselblad, V; McNulty, SE; Storrow, AB; Gibler, WB; Garvey, JL; Schreiber, DH; Tucker, JF; Ohman, EM. Comparison of 30-day outcome, resource use, and coronary artery disease severity in patients with suspected coronary artery disease with and without diabetes mellitus assigned to chest pain units. American Journal of Cardiology. 2003;91:1228-1230. (2003) Abstract

Al Suwaidi, J; Reddan, DN; Williams, K; Pieper, KS; Harrington, RA; Califf, RM; Granger, CB; Ohman, EM; Holmes, DR; GUSTO-IIb, GUSTO-III, PURSUIT. Global Use of Strategies to Open Occluded Coronary Arteries. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy, ; PARAGON-A Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974-980. (2002) Abstract

Anderson, RD; White, HD; Ohman, EM; Wagner, GS; Krucoff, MW; Armstrong, PW; Weaver, WD; Gibler, WB; Stebbins, AL; Califf, RM; Topol, EJ. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. American Heart Journal. 2002;144:81-88. (2002) Abstract

Aviles, RJ; Askari, AT; Lindahl, B; Wallentin, L; Jia, G; Ohman, EM; Mahaffey, KW; Newby, LK; Califf, RM; Simoons, ML; Topol, EJ; Berger, P; Lauer, MS. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. New England Journal of Medicine. 2002;346:2047-2052. (2002) Abstract

Batchelor, WB; Tolleson, TR; Huang, Y; Larsen, RL; Mantell, RM; Dillard, P; Davidian, M; Zhang, D; Cantor, WJ; Sketch, MH; Ohman, EM; Zidar, JP; Gretler, D; DiBattiste, PM; Tcheng, JE; Califf, RM; Harrington, RA. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation. 2002;106:1470-1476. (2002) Abstract

Brener, SJ; Zeymer, U; Adgey, AA; Vrobel, TR; Ellis, SG; Neuhaus, KL; Juran, N; Ivanc, TB; Ohman, EM; Strony, J; Kitt, M; Topol, EJ. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. Journal of the American College of Cardiology. 2002;39:377-386. (2002) Abstract

Cantor, WJ; Newby, LK; Christenson, RH; Tuttle, RH; Hasselblad, V; Armstrong, PW; Moliterno, DJ; Califf, RM; Topol, EJ; Ohman, EM; SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy Investigators. Prognostic significance of elevated troponin I after percutaneous coronary intervention. Journal of the American College of Cardiology. 2002;39:1738-1744. (2002) Abstract

Christenson, JT; Cohen, M; Ferguson, JJ; Freedman, RJ; Miller, MF; Ohman, EM; Reddy, RC; Stone, GW; Urban, PM. Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery. Annals of Thoracic Surgery. 2002;74:1086-1090. (2002) Abstract

Gibler, WB; Armstrong, PW; Ohman, EM; Weaver, WD; Stebbins, AL; Gore, JM; Newby, LK; Califf, RM; Topol, EJ; Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. Annals of Emergency Medicine. 2002;39:123-130. (2002) Abstract

Newby, LK; Alpert, JS; Ohman, EM; Thygesen, K; Califf, RM. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. American Heart Journal. 2002;144:957-980. (2002) Abstract

Savonitto, S; Granger, CB; Ardissino, D; Gardner, L; Cavallini, C; Galvani, M; Ottani, F; White, HD; Armstrong, PW; Ohman, EM; Pieper, KS; Califf, RM; Topol, EJ; GUSTO-IIb Investigators. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. Journal of the American College of Cardiology. 2002;39:22-29. (2002) Abstract

Wong, CK; White, HD; Wilcox, RG; Criger, DA; Califf, RM; Topol, EJ; Ohman, EM; GUSTO-III Investigators. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. Heart. 2002;88:357-362. (2002) Abstract

Aronow, HD; Topol, EJ; Roe, MT; Houghtaling, PL; Wolski, KE; Lincoff, AM; Harrington, RA; Califf, RM; Ohman, EM; Kleiman, NS; Keltai, M; Wilcox, RG; Vahanian, A; Armstrong, PW; Lauer, MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063-1068. (2001) Abstract

Cantor, WJ; Hellkamp, AS; Peterson, ED; Zidar, JP; Cowper, PA; Sketch, MH; Tcheng, JE; Califf, RM; Ohman, EM. Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes?. Journal of the American College of Cardiology. 2001;37:1883-1890. (2001) Abstract

Christenson, RH; Duh, SH; Roe, MT; Ohman, EM. Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies. Cardiovascular Toxicology. 2001;1:171-176. (2001) Abstract

Ferguson, JJ; Cohen, M; Freedman, RJ; Stone, GW; Miller, MF; Joseph, DL; Ohman, EM. The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. Journal of the American College of Cardiology. 2001;38:1456-1462. (2001) Abstract

Greenbaum, AB; Harrington, RA; Hudson, MP; MacAulay, CM; Wilcox, RG; Simoons, ML; Berdan, LG; Guerci, A; Cokkinos, DV; Kitt, MM; Lincoff, AM; Topol, EJ; Califf, RM; Ohman, EM. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. Journal of the American College of Cardiology. 2001;37:492-498. (2001) Abstract

Hirsh, J; Warkentin, TE; Shaughnessy, SG; Anand, SS; Halperin, JL; Raschke, R; Granger, C; Ohman, EM; Dalen, JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S-94S. (2001) Abstract

Hudson, MP; Granger, CB; Topol, EJ; Pieper, KS; Armstrong, PW; Barbash, GI; Guerci, AD; Vahanian, A; Califf, RM; Ohman, EM. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation. 2001;104:1229-1235. (2001) Abstract

Newby, LK; Ohman, EM; Christenson, RH; Moliterno, DJ; Harrington, RA; White, HD; Armstrong, PW; Van De Werf, F; Pfisterer, M; Hasselblad, V; Califf, RM; Topol, EJ. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation. 2001;103:2891-2896. (2001) Abstract

Newby, LK; Storrow, AB; Gibler, WB; Garvey, JL; Tucker, JF; Kaplan, AL; Schreiber, DH; Tuttle, RH; McNulty, SE; Ohman, EM. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation. 2001;103:1832-1837. (2001) Abstract

Ohman, EM; Harrington, RA; Cannon, CP; Agnelli, G; Cairns, JA; Kennedy, JW. Intravenous thrombolysis in acute myocardial infarction. Chest. 2001;119:253S-277S. (2001) Abstract

Ohman, EM; Peterson, E. Implications and challenges using practice guidelines for chronic angina. Annals of Internal Medicine. 2001;135:527-529. (2001) Abstract

Popma, JJ; Ohman, EM; Weitz, J; Lincoff, AM; Harrington, RA; Berger, P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001;119:321S-336S. (2001) Abstract

Roe, MT; Ohman, EM; Maas, AC; Christenson, RH; Mahaffey, KW; Granger, CB; Harrington, RA; Califf, RM; Krucoff, MW. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. Journal of the American College of Cardiology. 2001;37:9-18. (2001) Abstract

Singh, M; Reeder, GS; Ohman, EM; Mathew, V; Hillegass, WB; Anderson, RD; Gallup, DS; Garratt, KN; Holmes, DR. Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An Angiographic Trials Pool data experience. Journal of the American College of Cardiology. 2001;38:624-630. (2001) Abstract

Alexander, JH; Sparapani, RA; Mahaffey, KW; Deckers, JW; Newby, LK; Ohman, EM; Corbalán, R; Chierchia, SL; Boland, JB; Simoons, ML; Califf, RM; Topol, EJ; Harrington, RA. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA: Journal of the American Medical Association. 2000;283:347-353. (2000) Abstract

Herrmann, HC; Moliterno, DJ; Ohman, EM; Stebbins, AL; Bode, C; Betriu, A; Forycki, F; Miklin, JS; Bachinsky, WB; Lincoff, AM; Califf, RM; Topol, EJ. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. Journal of the American College of Cardiology. 2000;36:1489-1496. (2000) Abstract

Lincoff, AM; Harrington, RA; Califf, RM; Hochman, JS; Guerci, AD; Ohman, EM; Pepine, CJ; Kopecky, SL; Kleiman, NS; Pacchiana, CM; Berdan, LG; Kitt, MM; Simoons, ML; Topol, EJ. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2000;102:1093-1100. (2000) Abstract

Menon, V; Hochman, JS; Stebbins, A; Pfisterer, M; Col, J; Anderson, RD; Hasdai, D; Holmes, DR; Bates, ER; Topol, EJ; Califf, RM; Ohman, EM. Lack of progress in cardiogenic shock: lessons from the GUSTO trials. European Heart Journal. 2000;21:1928-1936. (2000) Abstract

Ohman, EM; Granger, CB; Harrington, RA; Lee, KL. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA: Journal of the American Medical Association. 2000;284:876-878. (2000) Abstract

Roe, MT; Harrington, RA; Prosper, DM; Pieper, KS; Bhatt, DL; Lincoff, AM; Simoons, ML; Akkerhuis, M; Ohman, EM; Kitt, MM; Vahanian, A; Ruzyllo, W; Karsch, K; Califf, RM; Topol, EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation. 2000;102:1101-1106. (2000) Abstract

Topol, EJ; Ohman, EM; Armstrong, PW; Wilcox, R; Skene, AM; Aylward, P; Simes, J; Dalby, A; Betriu, A; Bode, C; White, HD; Hochman, JS; Emanuelson, H; Vahanian, A; Sapp, S; Stebbins, A; Moliterno, DJ; Califf, RM. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation. 2000;102:1761-1765. (2000) Abstract

Cohen, MG; Granger, CB; Ohman, EM; Stebbins, AL; Grinfeld, LR; Cagide, AM; Elizari, MV; Betriu, A; Kong, DF; Topol, EJ; Califf, RM. Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Journal of the American College of Cardiology. 1999;34:1729-1737. (1999) Abstract

Anderson, RD; Ohman, EM; Holmes, DR; Harrington, RA; Barsness, GW; Wildermann, NM; Phillips, HR; Topol, EJ; Califf, RM. Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. Journal of the American College of Cardiology. 1998;32:936-941. (1998) Abstract

Gurbel, PA; Serebruany, VL; Shustov, AR; Bahr, RD; Carpo, C; Ohman, EM; Topol, EJ. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. Journal of the American College of Cardiology. 1998;31:1466-1473. (1998) Abstract

Newby, LK; Christenson, RH; Ohman, EM; Armstrong, PW; Thompson, TD; Lee, KL; Hamm, CW; Katus, HA; Cianciolo, C; Granger, CB; Topol, EJ; Califf, RM. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation. 1998;98:1853-1859. (1998) Abstract

Barsness, GW; Peterson, ED; Ohman, EM; Nelson, CL; DeLong, ER; Reves, JG; Smith, PK; Anderson, RD; Jones, RH; Mark, DB; Califf, RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. 1997;96:2551-2556. (1997) Abstract

Christenson, RH; Ohman, EM; Topol, EJ; Peck, S; Newby, LK; Duh, SH; Kereiakes, DJ; Worley, SJ; Alosozana, GL; Wall, TC; Califf, RM. Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. Circulation. 1997;96:1776-1782. (1997) Abstract

Ohman, EM; Tardiff, BE. Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. Importance and implications. JAMA: Journal of the American Medical Association. 1997;277:495-497. (1997) Abstract

Ohman, EM; Armstrong, PW; Christenson, RH; Granger, CB; Katus, HA; Hamm, CW; O'Hanesian, MA; Wagner, GS; Kleiman, NS; Harrell, FE; Califf, RM; Topol, EJ. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. New England Journal of Medicine. 1996;335:1333-1341. (1996) Abstract

Weaver, WD; White, HD; Wilcox, RG; Aylward, PE; Morris, D; Guerci, A; Ohman, EM; Barbash, GI; Betriu, A; Sadowski, Z; Topol, EJ; Califf, RM. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. JAMA: Journal of the American Medical Association. 1996;275:777-782. (1996) Abstract